Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population

Autores: Gupta Vinod H, Singh Meenakshi, Amarapurkar Deepak N, Sasi Preetha, Joshi Jyotsna M, Baijal Rajiv, Wangikar Pramod P, et al

Resumen

Background: The first line anti-tubercular (anti-TB) treatment normally involves isoniazid, rifampicin, pyrazinamide, and ethambutol. Clearance of these drugs depends on the activity of several enzymes such as N-acetyl transferase 2, cytochrome P450 oxidase and glutathione S-transferase (GST). Some of these enzymes are highly polymorphic leading to significant inter-individual variation in their activity thereby increasing the risk of drug induced hepatotoxicity (DIH). Aim: To investigate the possible association of anti-TB DIH with genetic polymorphism of GST genes in Western Indian population. Material and methods: A prospective case-control study was undertaken on patients who received anti-TB treatment. Cases (n = 50) were distinguished from controls (n = 246) based on occurrence of DIH during anti-tubercular treatment. A multiplex polymerase chain reaction was employed to identify homozygous null mutation at GSTM1 and GSTT1 loci. Results: Homozygous null mutation in GSTM1 gene alone or in both GSTM1 and T1 genes was found to be significantly associated with anti-TB DIH at p < 0.02 and p < 0.007, respectively, in our study population. Conclusions: This is the first study to report GSTM1 null and combined GSTM1 and T1 null genotypes to be risk factors of anti-TB DIH in Western Indian population. Screening of patients for these genotypes prior to anti-TB regimen would provide better control of hepatotoxicity.

Palabras clave: Drug induced hepatotoxicity. Phase II enzymes. Homozygous null mutation. Case-control study.

2014-03-01   |   281 visitas   |   Evalua este artículo 0 valoraciones

Vol. 12 Núm.6. Noviembre-Diciembre 2013 Pags. 959-965 Ann Hepatol 2013; 12(6)